IL143296A0 - Use of human prostate cell lines in cancer treatment - Google Patents

Use of human prostate cell lines in cancer treatment

Info

Publication number
IL143296A0
IL143296A0 IL14329699A IL14329699A IL143296A0 IL 143296 A0 IL143296 A0 IL 143296A0 IL 14329699 A IL14329699 A IL 14329699A IL 14329699 A IL14329699 A IL 14329699A IL 143296 A0 IL143296 A0 IL 143296A0
Authority
IL
Israel
Prior art keywords
cell lines
cancer treatment
human prostate
prostate cell
derivatives
Prior art date
Application number
IL14329699A
Other languages
English (en)
Original Assignee
Onyvax Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyvax Ltd filed Critical Onyvax Ltd
Publication of IL143296A0 publication Critical patent/IL143296A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5152Tumor cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/80Vaccine for a specifically defined cancer
    • A61K2039/884Vaccine for a specifically defined cancer prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL14329699A 1998-12-10 1999-12-09 Use of human prostate cell lines in cancer treatment IL143296A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9827104.2A GB9827104D0 (en) 1998-12-10 1998-12-10 New cancer treatments
PCT/GB1999/004129 WO2000033869A2 (en) 1998-12-10 1999-12-09 Use of human prostrate cell lines in cancer treatment

Publications (1)

Publication Number Publication Date
IL143296A0 true IL143296A0 (en) 2002-04-21

Family

ID=10843926

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14329699A IL143296A0 (en) 1998-12-10 1999-12-09 Use of human prostate cell lines in cancer treatment
IL143296A IL143296A (en) 1998-12-10 2001-05-22 Factor containing a line of prostate cells, preparations containing it and use in the treatment of prostate cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL143296A IL143296A (en) 1998-12-10 2001-05-22 Factor containing a line of prostate cells, preparations containing it and use in the treatment of prostate cancer

Country Status (19)

Country Link
US (3) US6972128B1 (cg-RX-API-DMAC7.html)
EP (1) EP1137422B1 (cg-RX-API-DMAC7.html)
JP (2) JP4949554B2 (cg-RX-API-DMAC7.html)
KR (1) KR20010090874A (cg-RX-API-DMAC7.html)
AT (1) ATE304365T1 (cg-RX-API-DMAC7.html)
AU (1) AU763485B2 (cg-RX-API-DMAC7.html)
CA (1) CA2354045C (cg-RX-API-DMAC7.html)
CZ (1) CZ300499B6 (cg-RX-API-DMAC7.html)
DE (1) DE69927286T2 (cg-RX-API-DMAC7.html)
ES (1) ES2249046T3 (cg-RX-API-DMAC7.html)
GB (1) GB9827104D0 (cg-RX-API-DMAC7.html)
HU (1) HUP0104568A3 (cg-RX-API-DMAC7.html)
IL (2) IL143296A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA01005816A (cg-RX-API-DMAC7.html)
NO (1) NO327044B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ512004A (cg-RX-API-DMAC7.html)
PL (1) PL201016B1 (cg-RX-API-DMAC7.html)
WO (1) WO2000033869A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200104164B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
GB9827103D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
WO2000071156A2 (en) * 1999-05-21 2000-11-30 Onyvax Limited New vaccine formulations-3
AU2001244341A1 (en) 2000-04-01 2001-10-15 Onyvax Limited New prostate cell lines
US6667479B2 (en) * 2001-06-01 2003-12-23 Raytheon Company Advanced high speed, multi-level uncooled bolometer and method for fabricating same
US20050019336A1 (en) 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment
JP2007503435A (ja) * 2003-08-26 2007-02-22 ベクトン・ディキンソン・アンド・カンパニー 治療薬の皮内送達法
CN101646455A (zh) 2007-02-07 2010-02-10 财团法人阪大微生物病研究会 用于癌症的治疗剂
EP2216041A4 (en) * 2007-11-20 2012-10-24 Nec Corp METHOD OF INDUCING A CYTOTOXIC T-CELL, CYTOTOXIC T-CELL INDUCTOR AND PHARMACEUTICAL COMPOSITION, AND VACCINE WITH THE INDUCTOR
AU2009200767A1 (en) * 2008-03-10 2009-09-24 Aristocrat Technologies Australia Pty Limited A gaming system and a method of gaming
US9974844B2 (en) * 2008-11-17 2018-05-22 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU677165B2 (en) * 1991-10-04 1997-04-17 Johns Hopkins University School Of Medicine, The The regulation of systemic immune responses utilizing cytokines and antigens
JPH05246889A (ja) * 1992-03-05 1993-09-24 Seitai Chiyousetsu Kenkyusho:Kk 制癌方法および制癌剤
AU2370195A (en) * 1994-04-28 1995-11-29 Scott Freeman Cell lines obtained by (in vivo) migration and by fusion with autoimmune cells
CA2214503C (en) * 1995-03-17 2002-05-07 The Regents Of The University Of California Method for treating tumors
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
EP0869803B1 (en) * 1995-12-28 2003-04-16 The Johns Hopkins University School Of Medicine Allogeneic paracrine cytokine tumor vaccines
ATE239781T1 (de) * 1996-02-02 2003-05-15 Us Gov Health & Human Serv Immortalisierte menschliche prostata- epithelzellen und klone und ihre verwendungen zur untersuchung und therapie von prostata-krebs
GB9620350D0 (en) * 1996-09-30 1996-11-13 Maudsley David J Cancer vaccine
US6207805B1 (en) * 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments

Also Published As

Publication number Publication date
GB9827104D0 (en) 1999-02-03
US6972128B1 (en) 2005-12-06
EP1137422B1 (en) 2005-09-14
HUP0104568A2 (hu) 2002-03-28
ATE304365T1 (de) 2005-09-15
KR20010090874A (ko) 2001-10-19
ES2249046T3 (es) 2006-03-16
CA2354045C (en) 2012-02-21
AU1668300A (en) 2000-06-26
US20120164099A1 (en) 2012-06-28
CZ300499B6 (cs) 2009-06-03
NO327044B1 (no) 2009-04-06
JP2002531520A (ja) 2002-09-24
WO2000033869A2 (en) 2000-06-15
NO20012634L (no) 2001-08-08
DE69927286D1 (de) 2005-10-20
WO2000033869A3 (en) 2000-10-12
AU763485B2 (en) 2003-07-24
MXPA01005816A (es) 2002-03-27
CA2354045A1 (en) 2000-06-15
PL348828A1 (en) 2002-06-17
US20050249756A1 (en) 2005-11-10
US8034360B2 (en) 2011-10-11
ZA200104164B (en) 2002-01-24
CZ20012032A3 (cs) 2001-10-17
DE69927286T2 (de) 2006-06-29
NO20012634D0 (no) 2001-05-29
HUP0104568A3 (en) 2004-05-28
NZ512004A (en) 2003-08-29
IL143296A (en) 2006-06-11
JP4949554B2 (ja) 2012-06-13
JP2012021028A (ja) 2012-02-02
EP1137422A2 (en) 2001-10-04
PL201016B1 (pl) 2009-02-27

Similar Documents

Publication Publication Date Title
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
MXPA03001645A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
MXPA04002593A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
MXPA03011985A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
NO20021830L (no) Sammensetninger egnet til å forhindre og behandle forkjölelse og influensaliknende symptomer samt fremgangsmåter vedfremstilling derav
IL143296A0 (en) Use of human prostate cell lines in cancer treatment
MXPA01010982A (es) Uso de phyllanthus para la estimulacion dirigida al objetivo del sistema inmune.
PT967987E (pt) Composicoes para o tratamento de tumores contendo extractos de cartilagem de tubarao e agentes antineoplasicos
MXPA04006572A (es) Terapia de combinacion antivirica.
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
IL136960A0 (en) Combination therapy for the treatment of migraine
AU6083301A (en) Treating eczema and/or psoriasis
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
IL131478A0 (en) Methods for treatment of scar tissue
IL139144A0 (en) Mycobacterial inhibitors
ZA200002338B (en) Combination therapy for the treatment of migraine.
ZA200003235B (en) Combination therapy for the treatment of migraine.
MXPA03001644A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
TR199802496T2 (xx) Konjestif kalp yetmezli�ini tedavi i�in form�lasyon.
ES2169986A1 (es) Uso de cdp-colina para el tratamiento profilactico de la isquemia cerebral.
IL136024A0 (en) Combination therapy for the treatment of migraine
PL1827403T3 (pl) Kompozycje do leczenia stanów patologicznych powierzchni oka
IL148336A (en) Medicaments that contain xenogeneic oligo and/or polyribonucleotides
MXPA05002477A (es) Asialo-interferones y el tratamiento de cancer de higado.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed